GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
122,100
-600 (-0.49%)
Sep 18, 2026, 9:35 AM KST

GC Biopharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-49,901-4,674-26,280-26,63265,453123,212
Depreciation & Amortization
85,56787,65581,03475,89965,09655,904
Loss (Gain) From Sale of Assets
-34,784-40,8672,5112,919-40,657-6,991
Asset Writedown & Restructuring Costs
94,86194,77018,088---
Loss (Gain) From Sale of Investments
-19,6539,380-6,665-1,209660333
Loss (Gain) on Equity Investments
10,865-14,58227,46438,43118,099-81,533
Provision & Write-off of Bad Debts
2,4004,3541,0792,7892,2466,980
Other Operating Activities
19,287-11,261-6,5942,64917,11947,052
Change in Accounts Receivable
60,457-27,41352,815-47,09313,219-10,756
Change in Inventory
-52,284-124,673-229,626-69,2341,721-14,919
Change in Accounts Payable
13,02019,10112,07722,6894,011-16,463
Change in Other Net Operating Assets
54,450107,67320,637-6,681-27,81323,160
Operating Cash Flow
184,28499,463-53,460-5,473119,154125,979
Operating Cash Flow Growth
-----5.42%250.20%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-96,517-72,362-31,992-79,087-57,996-102,321
Sale of Property, Plant & Equipment
474.052,109791.341,3191,540565.21
Cash Acquisitions
-7,344-62,261---74,05311,918
Divestitures
55,273-215.13---
Sale (Purchase) of Intangibles
-30,222-31,790-9,602-45,914-36,694-21,143
Investment in Securities
-21,344-26,828-24,226-25,139-31,332-30,734
Other Investing Activities
772.73957.112,269-1,423-723.710,133
Investing Cash Flow
-98,305-186,790-67,894-150,243-205,259-132,077

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-1,053,0631,221,1401,188,247806,151869,500
Long-Term Debt Issued
-168,555279,3875,00030,608209,429
Total Debt Issued
1,681,7111,221,6181,500,5271,193,247836,7591,078,929
Short-Term Debt Repaid
--1,067,201-1,169,646-1,059,800-721,740-992,600
Long-Term Debt Repaid
--24,142-217,342-9,419-135,590-102,423
Total Debt Repaid
-1,798,842-1,091,343-1,386,988-1,069,219-857,330-1,095,023
Net Debt Issued (Repaid)
-117,131130,275113,538124,028-20,571-16,094
Dividends Paid
-19,630-18,831-19,532-24,825-23,985-18,511
Other Financing Activities
24.54136.15-160.891,30842,075-6,665
Financing Cash Flow
-136,736111,58093,845100,512-2,481-41,270

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
8,2322,556366.22-455.397,8911,141
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
-42,52526,809-27,143-55,660-80,694-46,228

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
87,76727,101-85,452-84,56061,15823,658
Free Cash Flow Growth
----158.51%-
Free Cash Flow Margin
4.47%1.36%-5.09%-5.20%3.57%1.54%
Free Cash Flow Per Share
7690.042374.52-7487.16-7408.975358.562072.84
Levered Free Cash Flow
101,805-2,151-119,077-166,64252,929-10,238
Unlevered Free Cash Flow
133,63029,284-93,803-148,84064,424-2,425

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
37,38538,33238,13924,08019,37813,546
Cash Income Tax Paid
6,11611,1412,46819,03337,34918,867
Change in Working Capital
75,643-25,312-144,097-100,319-8,862-18,978